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Background: The aim of this study was to evaluate the clinical efficacy of postoperative radiotherapy (PORT),
administered using three-dimensional conformal radiotherapy (3D-CRT) and our institutional standard clinical target
volume (CTV) delineation, for completely resected stage IIIA(N2) non-small cell lung cancer (NSCLC).
Methods: From 2005 to 2012, consecutive patients with pT1-3N2 NSCLC who were treated with PORT employing
our institutional CTV delineation after complete surgery or who underwent complete resection in our hospital but
without PORT were identified. We excluded patients who had received neoadjuvant chemotherapy or radiation
therapy (RT). Kaplan-Meier estimates for locoregional recurrence-free survival (LRFS), distant metastasis-free survival
(DMFS) and overall survival (OS) were performed. In the OS estimation, patients who received epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) during follow-up were censored at the time of TKI initiation.
Results: Data from 70 patients in the PORT group and 287 in the non-PORT group were analysed. All 70 cases
received 3D-CRT following our institutional CTV guideline, with a median total dose of 50.4 Gy at 1.8 Gy/fraction.
At a median follow-up of 34.3 months for the PORT group and 31.2 months for the non-PORT group, PORT significantly
improved local control (5-yr LRFS 91.9% for PORT vs 66.4% for non-PORT, P < 0.001) and OS (5-yr OS 57.5% for PORT vs
35.1% for non-PORT, P = 0.003), whereas no differences in DMFS were noted (P = 0.18). In multivariable analyses, PORT
was independently associated with an improved LRFS (HR 0.2, P = 0.001) and OS (HR 0.4, P = 0.001). All patients
completed the planned RT dose without interruption of RT due to treatment-related complications.
Conclusions: Our data suggested that PORT administered using the 3D-CRT technique following our institutional
CTV delineation guideline resulted in a promising outcome with favourable survival for completely resected
IIIA(N2) NSCLC, after controlling for subsequent EGFR-TKI confounding in the OS analysis. Prospective trials are
needed to further corroborate these results.
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Completely resected non-small cell lung cancer (NSCLC)
patients with pathologically confirmed N2 disease are
considered to be a heterogeneous population [1], show-
ing 5-year survival rates ranging from 10% to 30% [2].
Systemic recurrence following surgery is one of the
major problems in stage IIIA(N2) patients, and the use
of postoperative chemotherapy (POCT) in stage IIIA
disease prolongs survival [3]. The value of postopera-
tive radiotherapy (PORT) for completely resected
NSCLC remains controversial, as the effect on survival
has been inconclusive [4-6]. A meta-analysis of PORT
published in 1998 [4] described a relative increase of
the risk of death with the addition of PORT for com-
pletely resected NSCLC. This detrimental effect was
evident among patients who exhibited no mediastinal
involvement, whereas in patients with stage III and
pN2 disease, a slight increase in survival was detected,
although the difference was not statistically significant.
Similar results were found when this meta-analysis was
updated in 2005 [5]. Recently, several large retrospect-
ive studies and a recently published randomized trial
have provided evidence of the possible benefit of PORT
in completely resected stage IIIA(N2) patients [7-13].
Several limitations of the previous prospective studies
included in the PORT meta-analysis have been recognized,
including the use of suboptimal radiation techniques and
wide irradiation portals. The quality of radiation therapy
(RT) was inferior to what is now available, with patients
being currently treated using linear accelerators and
the three-dimensional conformal radiotherapy (3D-CRT)
technique. The irradiation fields employed in most trials
have often been large and varying (typically including the
entire mediastinum and occasionally the supraclavicular
region or contralateral hilum). It has been hypothesized
that the toxicity reported in the meta-analysis was related
to large field sizes and the use of obsolete radiotherapy
techniques [14-16].
Currently, growing evidence suggests that PORT admin-
istered using the modern 3D-CRT technique has a
favourable effect on the survival of patients with pN2 dis-
ease [13,17]. However, there exists significant heterogeneity
within the reported studies with respect to the irradiation
fields employed for PORT because there is no clear con-
sensus on the definition of the extent of the clinical target
volume (CTV) [9-13]. To the best of our knowledge, there
is no solid evidence available for the PORT CTV designs
used in the currently published prospective trial [13] and
ongoing multi-centre phase III studies. Therefore, we de-
signed a patterns-of-failure study after complete surgery in
resected pN2 disease to evaluate the rationale of the pro-
posed PORT CTVs based on the most likely sites of nodal
failure, and the institutional standard CTV delineation for
PORT was developed in our hospital [18].The aim of the present study was to explore the clinical
efficacy of PORT administered using 3D-CRT techniques
and the institutional standard CTV delineation guideline
in our hospital for patients with completely resected
pathologic stage IIIA(N2) NSCLC, in attempt to provide
evidence for future phase III clinical trials.
Methods
Study population
The study group comprised consecutive patients with
completely resected pathologic stage IIIA(N2) NSCLC
who were treated with 3D-conformal PORT in accordance
with the institutional standard CTV delineation guideline
in our hospital between January 2005 and June 2012
(PORTgroup). During the same period, all consecutive pa-
tients with pathologic stage IIIA(N2) NSCLC who had
undergone complete resection in our hospital but did not
receive PORT were identified retrospectively (non-PORT
group). The inclusion criteria for the PORT group and the
non-PORT group were the same: complete resection
through a surgical procedure of either lobectomy or pneu-
monectomy; systematic nodal dissection or sampling with
a minimum of three N2 stations sampled or completely
dissected (one of which must be the subcarinal station)
[19]; and histologically proven NSCLC of stage pT1-
3N2M0 (according to the TNM classification in the UICC
7th ed. [20]). Complete resection was defined as surgical
resection with microscopically tumour-free resection mar-
gins (including the bronchial, venous and arterial stumps,
peribronchial soft tissue, any peripheral margin near the
tumour or additionally resected tissue) and systematic
nodal assessment. We excluded patients who died within
4 months of surgery to avoid the influence of perioperative
mortality on the study outcomes [7,11]. Patients who re-
ceived neoadjuvant therapy (chemotherapy and/or RT),
showed evidence of metastatic disease, or presented with
prior malignancies were excluded. Patients who received
adjuvant chemotherapy were included in both of the treat-
ment groups, but the administration of POCT was not
mandatory. In addition, patients were routinely assessed
through complete clinical and radiological evaluation prior
to the initiation of PORT. Patients who exhibited evidence
of residual disease, locoregional recurrence and/or distant
metastasis prior to PORT were excluded from the PORT
group. This study was approved by the Institutional Re-
view Board of Fudan University Shanghai Cancer Center.
Assessment and definition
The pretreatment evaluation generally included clinical as-
sessment, blood tests, chest computed tomography (CT)
scans, bronchoscopy, ultrasound or CT of the abdomen,
brain MRI and bone scans. Positron emission tomography
(PET)-CT scans were not used as part of the routine pre-
operative work-up. Patients with mediastinal lymph node
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sidered as having cN2 lesions.
The patients were generally followed every 3 months
after surgery for the first 2 years and every 6–12 months
thereafter. Regular follow-up evaluations included clin-
ical assessments, chest CT scans, and ultrasound or CT
of the abdomen. Treatment failures were determined by
the treating physician based on the available informa-
tion, including clinical assessments, imaging studies and/
or pathology reports. We obtained follow-up informa-
tion by conducting telephone surveys and by reviewing
electronic medical records in the clinic. Disease recur-
rence at the surgical margin, ipsilateral hilum, and/or
mediastinum was considered a local-regional failure
(LRF). All other sites of failure, including the supraclavi-
cular zone, contralateral hilum and distant organs, were
considered distant metastasis (DM) [21,22]. Data regarding
the timing of subsequent epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR-TKI) therapy for patients
with relapse or progressive disease were recorded.
Postoperative radiotherapy
All patients in the PORT group were treated using the
3D-CRT technique employing a linear accelerator with
6-MV X-rays. According to our institutional standard
PORT CTV delineation guideline, CTVs were delineated
separately for left- and right-sided lung cancers [18].
The CTV for left-lung cancers includes the bronchial
stump (BS) and lymph node stations (LNS) 2R, 2 L, 4R,
4 L, 5, 6, 7, and 10 to 11 L; and the CTV for right-lung
cancers includes the BS and LNS 2R, 4R, 7, and 10 to
11R (according to the 2009 International Association for
the Study of Lung Cancer (IASLC) lymph node map
[23]). The planning target volume (PTV) was defined as
the CTV plus the 0.5-0.8 cm margins. The prescribed
total PTV dose was 50.4 Gy, administered daily at
1.8 Gy per fraction, 5 days per week. In the case of cN2
disease or extracapsular node extension, the LNSs with
such findings were delineated as CTV-boost; then the
0.5-0.8 cm margin was added to create PTV-boost, and
the dose was increased for this volume up to 60.2 Gy.
Doses were prescribed to the PTV. The respective 99%
PTVs had to be covered by the 95% prescription dose,
and 95% PTVs had to be covered by the 100% prescrip-
tion dose. The dose constraints for the surrounding nor-
mal organs were as follows: a maximum dose to the
spinal cord of less than 45 Gy; a mean lung dose of less
than 15 Gy and less than 25% of the volume of the lung
receiving 20 Gy (V20); and a mean heart dose less than
30 Gy.
Statistical analyses
Comparisons of categorical variables between the groups
were carried out using Chi-square test. Locoregionalrecurrence-free survival (LRFS) was defined from the
day of surgery to the day of documented LRF or the last
follow-up. Distant metastasis-free survival (DMFS) was
defined from the day of surgery to the day of docu-
mented DM or the last follow-up. Disease-free survival
(DFS) was measured from the day of surgery to disease
recurrence, including LRF and DM events, or to the date
of death from any cause or the last follow-up. Overall
survival (OS) was measured from the day of surgery to
the date of death from any cause or the last follow-up.
In the OS estimation, patients who received EGFR-TKI
for progressive diseases during follow-up were censored
at the time of TKI initiation [24,25]. LRFS, DMFS, DFS
and OS rates were calculated by the Kaplan-Meier method
and compared by means of the log-rank test. Multivariable
Cox proportional hazard models (backward conditional
stepwise) were used to adjust for differing risk factor
distributions between the groups. The statistical ana-
lysis was computed using SPSS (version 17.0, SPSS Inc.,




Between January 2005 and June 2012, 72 patients with
completely resected pT1-3N2 NSCLC who underwent
3D-conformal PORT following our institutional CTV
delineation (PORT group) and 303 comparable patients
who underwent complete resection in our hospital but
did not receive PORT (non-PORT group) were identified
using the aforementioned selection criteria. Two patients
in the PORT group and 16 patients in the non-PORT
group were excluded due to incomplete follow-up data.
A total of 357 patients were included in the analysis
(Table 1). 30.8% (110/357) of the patients included in
the analysis had available PET-CT scans for preoperative
staging. Overall, the characteristics of the two groups
were comparable with regard to age, clinical N stage,
pathologic T stage, tumour location, histology and the
involved N2 stations. The application of POCT was rela-
tively well balanced across the two treatment groups; 58
patients (82.9%) in the PORT group and 209 (72.8%) in
the non-PORT group received ≥4 cycles of POCT with a
platinum-based regimen (P = 0.08). The median numbers
of lymph nodes resected in the PORT and non-PORT
groups were 16 (range: 3–54) and 20 (range: 5–67), re-
spectively. The median number of N2 stations resected
was 4 (range: 3–7) in both analysed groups. The propor-
tions of females and never/light ex-smokers were higher
in the PORT group than that in the non-PORT group.
More patients with >4 positive lymph nodes or with a
lymph node ratio (LNR, defined as the ratio of meta-
static to examined lymph node) >20% received PORT.
No patients who underwent pneumonectomy received
Table 1 Patient characteristics
Characteristics PORT Non-PORT P-value
No. (%) No. (%)
Patients (N) 70 287
Age (yr) 0.55
≤60 43 (61.4) 165 (57.5)
>60 27 (38.6) 122 (42.5)
Gender 0.03
Male 35 (50) 184 (64.1)
Female 35 (50) 103 (35.9)
Smoking history* 0.004
Never/light 46 (65.7) 134 (46.7)
Current/heavy 24 (34.3) 153 (53.3)
Clinical N status 0.45
cN0,1 35 (50) 158 (55.1)
cN2 35 (50) 129 (44.9)
Pathologic T stage 0.05
pT1 15 (21.4) 65 (22.7)
pT2 53 (75.7) 186 (64.8)
pT3 2 (2.9) 36 (12.5)
Type of surgery 0.01
Lobectomy 67 (95.7) 244 (85.0)
Sleeve lobectomy 3 (4.3) 9 (3.1)
Pneumonectomy 0 34 (11.9)
Tumor location 0.13
RUL 26 (37.1) 73 (25.4)
RML 9 (12.9) 24 (8.4)
RLL 12 (17.1) 50 (17.4)
LUL 14 (20.0) 90 (31.4)
LLL 9 (12.9) 50 (17.4)
Histology 0.56
Adenocarcinoma 47 (67.2) 169 (58.9)
Squamous 15 (21.4) 85 (29.6)
Adenosquamous 6 (8.6) 22 (7.7)
Large cell 1 (1.4) 9 (3.1)
Pleomorphic 1 (1.4) 2 (0.7)
N of positive nodes 0.04
≤4 30 (42.9) 162 (56.4)
>4 40 (57.1) 125 (43.6)
LNR 0.002
≤20% 22 (31.4) 150 (52.3)
>20% 48 (68.6) 137 (47.7)
Involved N2 stations 0.32
Single 31 (44.3) 146 (50.9)
Multiple 39 (55.7) 141 (49.1)
Table 1 Patient characteristics (Continued)
Cycles of POCT 0.08
<4 12 (17.1) 78 (27.2)
≥4 58 (82.9) 209 (72.8)
Subsequent EGFR-TKI therapy 0.004
Yes 22 (31.4) 47 (16.4)
No/unknown 48 (68.6) 240 (83.6)
Note: *Smoking history was categorized as never/light ex-smokers (<100
cigarettes smoked in the lifetime or smoked ≤10 pack-years, having
stopped for ≥15 years) or, the current/heavy ex-smokers.
Abbreviations: LNR = lymph node ratio (defined as the ratio of metastatic to
examined lymph nodes), RUL = right upper lobe, RML = right middle lobe,
RLL = right lower lobe, LUL = left upper lobe, LLL = left lower lobe, PORT =
postoperative radiotherapy, POCT = postoperative chemotherapy, EGFR-TKI =
epidermal growth factor receptor tyrosine kinase inhibitor.
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sequent EGFR-TKIs for progressive diseases than in the
non-PORT group (P = 0.004).
Clinical outcomes
For patients in the PORT and non-PORT groups, the
median follow-up times were 34.3 months (range, 17.9-
102.6) and 31.2 months (range, 12–101.4) for living pa-
tients, respectively. The Kaplan-Meier survival analysis
showed that PORT significantly improved locoregional
control rates compared with the non-PORT group (1-,
3-, 5-yr LRFS: 98.6%, 95.4%, 91.9% for PORT vs 88.5%,
71.1%, 66.4% for non-PORT, P < 0.001); however, no sig-
nificant differences in DMFS were noted (5-yr DMFS:
22.3% for PORT vs 21.7% for non-PORT, P = 0.18). The
median DFS times were 22.8 months and 18.6 months
in the PORT and non-PORT groups, respectively. The
results regarding 3- and 5-yr DFS showed a positive
trend in the PORT group: 42.1% and 21.6% in the PORT
group, respectively, vs 26.8% and 16.4% in the non-
PORT group (P = 0.04). The 1-, 3-, and 5-yr OS rates
were 98.6%, 75.3% and 57.5%, respectively, in the PORT
group, which were significantly higher than the corre-
sponding rates of 90.1%, 51.9% and 35.1% observed in
the non-PORT group (P = 0.003) (Figure 1).
Cox multivariate analysis demonstrated that PORT
was an independent prognostic factor for improved
LRFS (HR: 0.2, 95%CI 0.1-0.5, P = 0.001) and improved
OS (HR: 0.4, 95%CI 0.2-0.7, P = 0.001). Smoking history
(current/heavy ex-smokers: HR 2.6, 95%CI 1.6-4.4, P <
0.001), cN2 status (HR 1.7, 95%CI 1.0-2.7, P = 0.04) and
LNR >20% (HR 2.3, 95%CI 1.4-3.7, P = 0.001) were the
other factors independently associated with worse LRFS
(Table 2).
Patterns of first failure
Up to the last follow-up, a total of 248 patients experi-
enced disease recurrence, including 44 (62.9%) in the
PORT group and 204 (71.1%) in the non-PORT group
Figure 1 Comparison of (A) locoregional recurrence-free survival, (B) distant metastasis-free survival, (C) disease-free survival, and (D) overall survival
rates stratified by the PORT and non-PORT groups.
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mon pattern of failure in both treatment groups. In the
PORT group, LRF alone and DM alone occurred in 2.9%
(2/70) and 58.6% (41/70) patients, respectively, and 1.4%
(1/70) patients exhibited concurrent LRF and DM. In
the non-PORT group, 11.1% (32/287) patients exhibited
LRF alone; 50.2% (144/287) exhibited DM alone; and
9.8% (28/287) exhibited concurrent LRF and DM. There
was a significant reduction in LRF associated with PORT
(P = 0.03), but not in the supraclavicular nodes (P = 0.22)
or distant metastases (P = 0.21).
Complications
To date, 143 patients in the non-PORT group have died:
139 (97.2%) from cancer-related causes and 4 (2.8%) from
causes unrelated to cancer (cerebrovascular accident inone case, pulmonary infection in one case and coronary
artery heart disease in two cases). In the PORT group, 26
patients died, and all of these deaths were cancer-related.
All patients completed the planned RT dose without inter-
ruption or discontinuation of RT due to treatment-related
complications. No other severe late complications were
encountered during follow-up.
Discussion
A growing number of more recent publications have
bolstered the use of modern PORT for completely
resected stage IIIA(N2) NSCLC [26,27]. However, these
reports did not contain detailed information regarding
RT, especially concerning the PORT treatment volume.
To our knowledge, with the introduction of our institu-
tional standard PORT CTV delineation guideline [18],
Table 2 Univariate and multivariate analyses of factors affecting locoregional recurrence-free survival and overall
survival (all patients, N = 357)
Characteristics No. Locoregional recurrence-free survival Overall survival
Univariable Multivariate Univariable Multivariate
5-y (%) P HR (95% CI) P 5-y (%) P HR (95% CI) P
Age (yr) 0.69 0.99 0.07 0.4
≤60 208 73.3 1 40.0 1
>60 149 70.0 1.0 (0.6-1.6) 37.6 1.2 (0.8-1.6)
Gender <0.001 0.57 <0.001 <0.001
Male 219 64.3 1 32.5 1
Female 138 83.4 0.8 (0.4-1.7) 50.7 0.5 (0.3-0.7)
Smoking history <0.001 <0.001 0.008 0.37
Never/light 180 82.6 1 39.9 1
Current/heavy 177 60.9 2.6 (1.6-4.4) 36.0 0.8 (0.5-1.3)
Clinical N status 0.002 0.04 0.003 0.27
cN0,1 193 80.4 1 50.4 1
cN2 164 61.4 1.7 (1.0-2.7) 26.5 1.2 (0.9-1.7)
Pathologic T stage 0.11 0.6 0.18 0.77
pT1 80 81.4 1 45.4 1
pT2 239 70.7 1.0 (0.5-1.9) 39.9 0.9 (0.6-1.4)
pT3 38 59.1 1.4 (0.6-3.1) 21.8 1.1 (0.6-1.9)
Type of surgery 0.6 0.26 <0.001 0.24
Lobectomy 323 72.7 1 42.8 1
Pneumonectomy 34 65.6 0.6 (0.3-1.4) 12.8 1.3 (0.8-2.2)
Histology 0.01 0.23 0.018 0.05
Non-squamous 257 76.7 1 44.3 1
Squamous 100 59.4 1.4 (0.8-2.3) 28.1 1.4 (1.0-2.0)
N of positive nodes 0.002 0.48 <0.001 0.68
≤4 192 80.9 1 53.2 1
>4 165 60.8 1.3 (0.6-2.7) 21.9 1.1 (0.7-1.9)
LNR 0.003 0.001 <0.001 <0.001
≤20% 172 81.5 1 55.5 1
>20% 185 62.7 2.3 (1.4-3.7) 24.7 2.4 (1.7-3.3)
Involved N2 stations 0.1 0.75 <0.001 0.12
Single 177 76.1 1 56.0 1
Multiple 180 68.0 0.9 (0.5-1.6) 23.3 1.4 (0.9-2.0)
Cycles of POCT 0.9 0.79 0.001 <0.001
<4 90 69.5 1 29.8 1
≥4 267 72.7 1.1 (0.6-1.9) 41.3 0.5 (0.3-0.7)
PORT <0.001 0.001 0.003 0.001
No 287 66.4 1 35.1 1
Yes 70 91.9 0.2 (0.1-0.5) 57.5 0.4 (0.2-0.7)
Abbreviations: LNR = lymph node ratio, PORT = postoperative radiotherapy, POCT = postoperative chemotherapy, HR = hazard ratio, CI = confidence interval.
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PORT, administered using the 3D-CRT technique and the
institutional standard CTV delineation design based on
the patterns of local-regional failure data, for completelyresected stage IIIA(N2) NSCLC. In the present study, all
of the patients included in the PORT group in the analysis
were treated using a linear accelerator with the 3D-CRT
technique. Moreover, the underlying strength of this study
Table 3 Patterns of first failure
Pattern of first recurrence PORT Non-PORT P-value
No. (%) No. (%)
All patients (N) 70 287
Recurrence 44 (62.9) 204 (71.1) 0.18
Local-regional failure alone 2 (2.9) 32 (11.1) 0.03
Local-regional failure & Distant Metastasis 1 (1.4) 28 (9.8) 0.02
Distant Metastasis alone 41 (58.6) 144 (50.2) 0.21
Supraclavicular lymph node alone 4 (5.7) 8 (2.8) 0.22
Abbreviations: PORT = postoperative radiotherapy
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as applied herein [18]. Potential advantages include the
following: (1) the PORT CTV delineation based on the
patterns of failure data might be more reasonable and ap-
propriate; (2) this CTV delineation guideline strictly de-
fines LNSs included in the CTV, thus making it more
consistent and reproducible in clinical practice; and (3)
the design of treatment fields tailored to the area most-at-
risk for recurrence will reduce the irradiation volume (not
including LNSs 1, 3A, 3P, 8, and 9 in our institutional
CTV delineation [18]). Thus, it would be of value to assess
the efficacy of PORT using the 3D-CRT technique and
this institutional standard CTV delineation guideline for
completely resected stage IIIA(N2) NSCLC patients.
Prior studies reporting the outcomes of completely
resected pN2 patients are outlined in Table 4. We found
that the patients treated in both groups analysed in our
study (5-yr OS, 57.5% for PORT and 35.1% for non-PORT)
yielded superior OS compared with those in previously
reported studies [7-13]. The following may be possible
explanations for why our survival results in both treat-
ment groups appear to be better than their corresponding
historical controls. First, improved survival might be sec-
ondary to better patient selection, as a homogeneous
group of patients who underwent complete resection ofTable 4 Rates of overall survival and locoregional recurrence
Author Year Stage No. of patients
SEER [7] 2006 pN2 1987
ANITA [8] 2008 pN2 106(observation
118(chemother
Zou et al. [9] 2010 pN2 183
Scotti et al. [10] 2010 pN2 175
Dai et al. [11] 2011 IIIA-N2 221
Mantovani et al. [12] 2013 pN2 66
Shen et al. [13] 2014 IIIA-N2 135
Note: *indicates crude LRR rates. Abbreviations: NS = not stated, OS = overall survival, L
radiotherapy, SEER = Surveillance, Epidemiology, and End Results, ANITA = Adjuvant NaNSCLC and systematic nodal assessment was selected in
our study. Second, this difference might be due to the in-
clusion of a majority of cases receiving adjuvant chemo-
therapy in our study (all patients in the PORT group and
85% in the non-PORT group received POCT). The
ANITA study [8] also demonstrated an advantage of adju-
vant chemoradiotherapy in completely resected patients
with pN2 disease. It was reported that 5-yr OS was 47.4%
under the use of adjuvant chemoradiotherapy, which was
relatively comparable to the results of our analysis. Third,
the improvement of survival observed in the PORT group
likely depends on the application of our institutional CTV
delineation guideline, leading to relatively small-sized
PORT fields tailored to the area most-at-risk for recur-
rence after surgery, with good consistency in clinical prac-
tice. Miles et al. [14] attempted to estimate the field size
dependence of RT-induced mortality and tumour control
in the postoperative setting. It has been shown that RT-
induced mortality is strongly dependent on the field size,
which may partly offset the OS benefit afforded by PORT.
The incongruity between an improvement in local control
and a decrease in survival may have been secondary to
RT-induced complications.
Our results showed that the locoregional recurrence
(LRR) rate was reduced from 33.6% to 8.1% with therates after complete resection in pN2 NSCLC
5-y OS (%) 5-y LRR rates (%)
S S + PORT S S + PORT
20 27 NS
) 16.6 21.3 42.1* 22.1*
apy) 34 47.4 25.7* 14.6*
22.2 30.5 66 27
NS 44 20
30.6 36.6 53 36
NS 37 NS 28
27.5 37.9 49.3* 27.3*
RR = locoregional recurrence, S = surgery, S + PORT = surgery plus postoperative
velbine International Trialist Association.
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tients who received PORT was 57.5%, which was obviously
higher than in patients not receiving PORT (5-yr OS,
35.1%). A similar reduction in LRR rates with a survival
benefit was reported by previous retrospective series
[7-9,11]. Our findings are also congruent with a recent
meta-analysis study [17] echoing a similar increase in local
control and OS for completely resected stage IIIA(N2)
NSCLC. In this meta-analysis, it was reported that the ap-
plication of PORT using modern techniques was esti-
mated to reduce the LRF rate to 10% and increase
absolute 5-year OS by 13% [17].
The type of disease failure pattern predominated by DM
is also quite similar to the results reported in other trials
[9-12]. The patterns of failure outcomes after surgery with
or without PORT reported herein are in keeping with the
clinical efficacy of PORT as well, demonstrating that PORT
is able to reduce locoregional recurrences, but not in supra-
clavicular nodes or distant metastases. Of note, distant me-
tastases remain more frequent in completely resected
pIIIA(N2) disease, despite the addition of PORT, thereby
encouraging further exploration. It is possible that patients
with NSCLC have occult systemic disease, especially in
pN2 stages, and that PORT alone is not adequate to confer
a survival benefit without effective systemic control by
POCT. In the light of our data, it can be concluded that the
major problem for this patient population remains the high
risk of distant metastases, indicating the necessity for the
development of optimal adjuvant or systemic treatment
strategies.
The current study is observational in nature and as a re-
sult cannot prove a direct causal relationship between
PORT and prolonged survival. However, this link is highly
plausible for the following three major reasons. First, it
was demonstrated that PORT was independently asso-
ciated with improved OS according to the multivariate
analysis. Second, although the baseline data were not
balanced in the two treatment groups, these baseline
imbalances might bias our results towards either the
PORT or non-PORT group. In our study group, patients
whose tumour characteristics (>4 positive lymph nodes
and LNR >20%) were perceived to be worse might have
been referred for PORT more often. Third, the fact that
EGFR-TKI therapy subsequently administered for relapse
or progressive disease might obscure improved survival
should be considered and accounted for in the evaluation
of OS endpoints in current clinical practice. Thus, we
attempted to control for the disparity in subsequent
EGFR-TKI therapy between the two treatment groups by
applying a censoring approach at the OS estimation
[24,25]. This is one of the main differences between our
study and most other studies, including a recently pub-
lished small randomized trial conducted in China [13]. In
consideration of these factors, the application of PORTusing the 3D-CRT technique and our institutional stand-
ard CTV delineation guideline might confer a significant
survival advantage for completely resected stage IIIA(N2)
patients based on our present descriptive data.
In the present study, several clinical parameters (current/
heavy ex-smoker, cN2 status and LNR >20%) were identi-
fied as indicators of a high risk of LRF after complete
surgery in resected pN2 patients. These findings of this
study are in line with the results of previous studies on
the prognosis of completely resected IIIA(N2) patients
[1,28-30]. The identification of high-risk prognostic fac-
tors for LRF after complete surgery could be applied to
individualized clinical decision making (as completely
resected patients with pN2 disease can have different
prognoses) and in stratifying the randomization applied
in clinical trials.
We acknowledge that there are some limitations in-
herent to this retrospective study, such as selection
bias, missing data and inconsistent follow-up intervals.
Comparisons between the PORT and non-PORT groups
have been hampered by the retrospective nature of the
study and difficulty in controlling for confounding vari-
ables. The two populations were not well-balanced with
respect to several clinicopathologic factors. In fact,
there existed both favourable and adverse prognostic
confounders that may have biased the results towards
either the PORT or non-PORT group. Furthermore, we
could not differentiate which factors among these poten-
tial confounders presented larger values and significantly
contributed to the outcomes presented herein. Another
important limitation was that the subsequent EGFR-TKI
therapy administered for relapse or progressive disease
after complete surgery was not strictly controlled for and
was not well-balanced in the two groups. It was noted that
more patients in the PORT group received EGFR-TKI
than in the non-PORT group, which might result in a bias
towards improved survival results. However, we have
taken appropriate steps, including statistical consider-
ations (censoring the analysis at the time of TKI initiation
in the OS estimation), in an attempt to control for the po-
tential impact of this disparity on OS. Finally, our study is
limited by the relatively small number of patients analysed
in the PORT group. Therefore, there is still a need for a
prospective study to validate the efficacy of 3D-conformal
PORT in accordance with our institutional standard CTV
delineation guideline.
Conclusions
Our data suggested that PORT administered using the
3D-CRT technique following our institutional standard
CTV delineation guideline resulted in promising out-
comes regarding local control and survival improve-
ments for completely resected stage IIIA(N2) NSCLC
patients, after controlling for the confounding effect of
Feng et al. BMC Cancer  (2015) 15:348 Page 9 of 10subsequent EGFR-TKI therapy in the OS analysis. Pro-
spective and comprehensive trials are needed to further
corroborate these results. This report may lay the
groundwork for future phase III clinical trials of 3D-
conformal PORT following the standard CTV delineation
guideline.
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